Erratum: Identifying an ovarian cancer cell hierarchy regulated by bone morphogenetic protein 2 (Proceedings of the National Academy of Sciences of the United States of America (2015) 112 (E6882–E6888) DOI: 10.1073/pnas.1507899112);Identifying an ovarian cancer cell hierarchy regulated by bone morphogenetic protein 2

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 50, 2015, Pages E6882-E6888

  Choi, Yun Jung ^a,c   Ingram, Patrick N ^b   Yang, Kun ^a   Coffman, Lan ^a   Iyengar, Mangala ^b   Bai, Shoumei ^a   Thomas, Dafydd G ^a   Yoon, Euisik ^b   Buckanovich, Ronald J ^a,b   Eaves, Connie J ^d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Konkuk University   (South Korea)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

BMP2; Cancer stem cells; Differentiation capacity hierarchical; Ovarian cancer

Indexed keywords

ALDEHYDE DEHYDROGENASE; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; CD133 ANTIGEN; CISPLATIN; NOGGIN; ANTINEOPLASTIC AGENT; BMP2 PROTEIN, HUMAN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; PROM1 PROTEIN, HUMAN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL EXPANSION; CONTROLLED STUDY; ELECTRIC POTENTIAL; FEEDBACK SYSTEM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CELL PROLIFERATION; GENE SILENCING; GENETICS; METABOLISM; MICROFLUIDICS; OVARIAN NEOPLASMS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

AC133 ANTIGEN; ALDEHYDE DEHYDROGENASE; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BONE MORPHOGENETIC PROTEIN 2; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; GLYCOPROTEINS; HUMANS; MICROFLUIDICS; OVARIAN NEOPLASMS; PEPTIDES;

EID: 84950127824     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.2117843118     Document Type: Erratum

References (37)

1. Burgos-Ojeda D., Rueda BR, Buckanovich R.J. (2012) Ovarian cancer stem cell markers: Prognostic and therapeutic implications. Cancer Lett 322(1):1-7.
2. Schepers AG, et al (2012) Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337 (6095):730-735.
3. Driessens G, Beck B, Caauwe A., Simons BD, Blanpain C. (2012) Defining the mode of tumour growth by clonal analysis. Nature 488 (7412):527-530.
4. Chen J, et al (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488 (7412):522-526.
5. Gupta PB, et al (2011) Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146(4):633-644.
6. Odoux C, et al (2008) A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res 68(17):6932-6941.
7. Wang W, et al (2014) Dynamics between cancer cell subpopulations reveals a model coordinating with both hierarchical and stochastic concepts. PLoS One 9(1):e84654.
8. Sottoriva A, et al (2010) Cancer stem cell tumor model reveals invasive morphology and increased phenotypical heterogeneity. Cancer Res 70(1):46-56.
9. Stewart JM, et al (2011) Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci USA 108(16):6468-6473.
10. Foster R, Buckanovich RJ, Rueda B.R. (2013) Ovarian cancer stem cells: Working towards the root of stemness. Cancer Lett 338(1):147-157.
11. Kryczek I, et al (2012) Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer 130(1):29-39.
12. Mizuno T, et al (2015) Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species. Gynecol Oncol 137(2):299-305.
13. Landen CN, Jr, et al. (2010) Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 9(12):3186-3199.
14. Steg AD, et al (2012) Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 18(3):869-881.
15. Baba T, et al (2009) Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 28(2):209-218.
16. Curley MD, et al (2009) CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 27(12):2875-2883.
17. Silva IA, et al (2011) Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 71(11):3991-4001.
18. Dobbin ZC, et al (2014) Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer. Oncotarget 5(18): 8750-8764.
19. Flesken-Nikitin A., et al (2013) Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature 495 (7440):241-245.
20. Chung J, Kim YJ, Yoon E. (2011) Highly-efficient single-cell capture in microfluidic array chips using differential hydrodynamic guiding structures. Appl Phys Lett 98(12): 123701.
21. Chung J, Ingram PN, Bersano-Begey T, Yoon E. (2014) Traceable clonal culture and chemodrug assay of heterogeneous prostate carcinoma PC3 cells in microfluidic single cell array chips. Biomicrofluidics 8(6):064103.
22. Ma W, et al (2013) Lin28 regulates BMP4 and functions with Oct4 to affect ovarian tumor microenvironment. Cell Cycle 12(1):88-97.
23. McLean K, et al (2011) Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest 121(8):3206-3219.
24. Min SK, Yoon GH, Joo J.H., Sim SJ, Shin H.S. (2014) Mechanosensitive physiology of Chlamydomonas reinhardtii under direct membrane distortion. Sci Rep 4:4675.
25. Le Page C., et al (2006) Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer. Br J Cancer 94(3): 436-445.
26. Moll F, et al (2006) Chordin is underexpressed in ovarian tumors and reduces tumor cell motility. FASEB J 20(2):240-250.
27. Le Page C., et al (2009) BMP-2 signaling in ovarian cancer and its association with poor prognosis. J Ovarian Res 2:4.
28. Ehata S, Yokoyama Y, Takahashi K., Miyazono K. (2013) Bidirectional roles of bone morphogenetic proteins in cancer: another molecular Jekyll and Hyde? Pathol Int 63(6):287-296.
29. Park Y, et al (2008) The bone morphogenesis protein-2 (BMP-2) is associated with progression to metastatic disease in gastric cancer. Cancer Res Treat 40(3):127-132.
30. Chapellier M, et al (2015) Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell response. Stem Cell Rep 4(2):239-254.
31. Cooper GS, Kou T.D. (2013) Risk of cancer after lumbar fusion surgery with recombinant human bone morphogenic protein-2 (rh-BMP-2). Spine 38(21):1862-1868.
32. Carragee EJ, et al (2013) Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis. J Bone Joint Surg Am 95(17):1537-1545.
33. Carragee EJ, Hurwitz EL, Weiner B.K. (2011) A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: Emerging safety concerns and lessons learned. Spine J 11(6):471-491.
34. Calva-Cerqueira D., et al (2010) Discovery of the BMPR1A promoter and germline mutations that cause juvenile polyposis. Hum Mol Genet 19(23):4654-4662.
35. Owens P, et al (2012) Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators. Proc Natl Acad Sci USA 109(8):2814-2819.
36. Pulaski HL, et al (2009) Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med 7:49.
37. Chen YC, Ingram P, Yoon E. (2014) Electrolytic valving isolation of cell co-culture microenvironment with controlled cell pairing ratios. Analyst (Lond) 139(24):6371-6378.